Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.39 Consensus PT from Analysts

Key Points

• Voyager Therapeutics, Inc. has received an average recommendation of "Buy" from eight analysts, with a one-year price target averaging $13.39.
• Institutional investors have increased their stakes in Voyager Therapeutics, with Allspring Global Investments growing its position by 53.8% in the first quarter of the year.
• The company's stock is currently trading at $3.20, down 2.1%, and it reported a significant earnings miss with a loss of ($0.53) per share in its last quarterly report.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have earned an average recommendation of "Buy" from the eight research firms that are presently covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $13.39.

Separately, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th.

Voyager Therapeutics Price Performance

Shares of VYGR stock traded down $0.23 during trading hours on Wednesday, reaching $2.96. The stock had a trading volume of 872,821 shares, compared to its average volume of 495,108. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $8.53. The firm has a 50-day simple moving average of $3.19 and a 200-day simple moving average of $3.72. The firm has a market capitalization of $163.81 million, a PE ratio of -2.03 and a beta of 0.85.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). Voyager Therapeutics had a negative net margin of 126.49% and a negative return on equity of 27.36%. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $13.55 million. On average, equities analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in VYGR. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 0.7% during the first quarter. Armistice Capital LLC now owns 5,436,000 shares of the company's stock worth $18,374,000 after acquiring an additional 40,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in Voyager Therapeutics by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company's stock worth $18,232,000 after purchasing an additional 29,014 shares during the period. Farallon Capital Management LLC increased its holdings in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock worth $14,576,000 after purchasing an additional 278,700 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Voyager Therapeutics by 24.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock valued at $7,828,000 after purchasing an additional 275,571 shares during the period. Finally, Vestal Point Capital LP lifted its holdings in shares of Voyager Therapeutics by 1.6% in the first quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company's stock valued at $4,223,000 after purchasing an additional 19,418 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.